Feb 4 (Reuters) - IMV Inc IMV.TO :
* CLINICAL TRANSLATIONAL DATA SUPPORTING DPX-SURVIVAC MECHANISM OF ACTION TO BE PRESENTED AT 2020 ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM
* IMV INC - DPX-SURVIVAC GENERATED STRONG, SUSTAINED AND FUNCTIONAL SURVIVIN-SPECIFIC T CELL RESPONSE IN 80% OF PATIENTS' BLOOD SAMPLES
* IMV INC - CLINICAL ANTI-TUMOR RESPONSES WERE CORRELATED WITH INCREASED INFILTRATION OF T CELLS INTO TUMORS FOLLOWING TREATMENT WITH DPX-SURVIVAC
* IMV INC - ANTIGEN-SPECIFIC T CELLS RETAINED THEIR FUNCTIONALITY THROUGHOUT DURATION OF TREATMENT